got it, thanks Koo!

"Resverlogix initially planned to study apabetalone to improve clinical status in SARS-CoV-2 infected patients, but will now also examine if it can treat heart damage."

This is rather material news, no?   IMO, last we heard, about 4 weeks ago, the FDA registration for a quick 30-day, 100-patient Covid trial would be done within a week.  Now I hear about a dramatic change/expansion to the original "quick" trial from some small newspaper from the other side of the planet? (no offense to the Aussies here.. )

Maybe I'm wrong and this is not material.  I guess I just wish that for once Don's forward-looking statements (some would call hype) would work out as promised, just for once even.  So frustrating waiting for overdue progress and news thereof and then finding out indirectly that exasperated  shareholders are actually being kept in the dark on significant corporate developments.